



**NORTH CAROLINA GENERAL ASSEMBLY  
AMENDMENT  
Senate Bill 711**

AMENDMENT NO. \_\_\_\_\_  
(to be filled in by  
Principal Clerk)

S711-ABP-33 [v.2]

Page 1 of 3

Amends Title [NO]  
Fourth Edition

Date \_\_\_\_\_, 2021

Senator \_\_\_\_\_

moves to amend the bill on page 17, lines 11-23, by rewriting the lines to read:

**""§ 90-113.129. Medical cannabis center restrictions.**

(a) Hours. – A medical cannabis center licensed under this Article shall not sell cannabis or cannabis-infused products between the hours of 7:00 P.M. and 7:00 A.M.

(b) Location. – A medical cannabis center shall not be located within 1,000 linear feet of the property line of any of the following places:

(1) A church.

(2) A child care facility as defined in G.S. 110-86(3).

(3) A public school unit or any nonpublic school as defined in Part 1 or Part 2 of Article 39 of Chapter 115C of the General Statutes.

(4) A community college or the facilities of The University of North Carolina and the grounds of those facilities as defined in G.S. 143-597(a)(6).

(c) Limited Entry. – Entry to medical cannabis centers shall be strictly limited to qualified patients, designated caregivers, and persons whose job duties require their presence in the medical cannabis center, including employees and contractors of the medical cannabis center and state employees with an inspection or regulatory role. The Commission may set other limitations as necessary to protect the public.

(d) Employee Age. – Employees of a medical cannabis center must be twenty-one years of age or older.

(e) Consumption Prohibited. – Consumption of cannabis or cannabis-infused products on the site of a medical cannabis center is prohibited.

(f) Products. – The only products that may be sold in a medical cannabis center are cannabis and cannabis-infused products and paraphernalia relating to the administration of cannabis and cannabis-infused products.

(g) Visibility Restriction. – Cannabis, cannabis-infused products, and paraphernalia shall not be visible to the public from the outside of the medical cannabis center.

(h) Delivery. – The Commission may establish rules to allow the delivery of cannabis, cannabis-infused products, and paraphernalia used to administer cannabis products by medical cannabis centers to the home of a qualified patient or a designated caregiver in a manner that ensures public safety, the safety of persons delivering the products, and the prevention of diversion."



\* S 7 1 1 - A B P - 3 3 - V - 2 \*

**NORTH CAROLINA GENERAL ASSEMBLY**  
**AMENDMENT**  
**Senate Bill 711**

AMENDMENT NO. \_\_\_\_\_  
(to be filled in by  
Principal Clerk)

S711-ABP-33 [v.2]

Page 2 of 3

and on page 17, lines 24-43, by rewriting the lines to read:

**""§ 90-113.130. Testing of cannabis and cannabis-infused products.**

(a) The Department shall establish standards for and shall license up to five independent testing laboratories to test cannabis and cannabis-infused products that are to be sold in the State. An independent testing laboratory shall analyze a representative sample of all cannabis or cannabis-infused products before the sale or transfer to a medical cannabis center by a production facility. An independent testing laboratory shall report the results of all testing required by the Department to the Department.

(b) An independent testing laboratory shall be responsible for selecting, picking up, and testing product samples.

(c) The Department shall adopt rules to establish the following, at a minimum:

- (1) Standards for testing cannabis and cannabis-infused products, including active ingredient analyses, potency analyses, homogeneity requirements, and specifying prohibited concentrations of heavy metals, pesticides, residual solvents, microbiological contaminants, mycotoxins, and other contaminants that are injurious to human health.
- (2) Standards for independent testing laboratories, including requirements for equipment and qualifications for personnel.
- (3) Standards and requirements necessary for an independent testing laboratory to be licensed and for the renewal, suspension, and revocation of the license.
- (4) Remedial actions to be taken if the representative sample does not meet the standards established by the Department.
- (5) The amount of the licensing fee payable to the Department by an independent testing laboratory.";

And on page 18, lines 3-4, by inserting the following between the lines:

"(c) A medical cannabis supplier or medical cannabis center shall not:

- (1) Advertise in any manner that is viewable or can otherwise be perceived in a public space, including but not limited to billboards, bus wraps, signs on vehicles or benches, adopt-a-highway signs, or any format that may be viewable from sidewalks, walkways, or roads.
- (2) Distribute handbills in public areas.
- (3) Advertise on television, radio, print, digital, or electronic media.
- (4) Engage in advertising via marketing directed towards location-based devices or electronic devices, including but not limited to cellular phones.
- (5) Engage in any form of advertising which promotes the application or registration of people as qualified patients or promotes the services of a physician or any other party which facilitates such application or registration.
- (6) Publicly sponsor sporting events, concerts, or other community or cultural events.
- (7) Sell or give away promotional products such as t-shirts or any other items containing the name of the medical cannabis center.

**NORTH CAROLINA GENERAL ASSEMBLY  
AMENDMENT  
Senate Bill 711**

AMENDMENT NO. \_\_\_\_\_  
(to be filled in by  
Principal Clerk)

S711-ABP-33 [v.2]

Page 3 of 3

1           (8) Make therapeutic or health benefit claims related to cannabis or  
2           cannabis-infused products.

3           (d) The Commission may take action against a licensee or designated retailer who  
4           engages in non-conforming signage or advertising, including specifying a period of time by  
5           which the licensee or designated retailer shall cease or remove the non-compliant signage or  
6           advertising or risk a fine, suspension of the license, or both.";

7  
8           and by renumbering the remaining subsections of G.S. 90-113.131 accordingly;

9  
10          and on page 18, lines 47-48, by inserting the following between the lines:

11           "(7) The batch number and the harvest number from which cannabis originates.

12           (8) The name of the qualified patient.

13           (9) The name of the physician who issued the written certification.

14           (10) The recommended dose according to the written certification."

15  
16  
17  
18  
19  
20  
21  
  
SIGNED \_\_\_\_\_  
Amendment Sponsor

SIGNED \_\_\_\_\_  
Committee Chair if Senate Committee Amendment

ADOPTED \_\_\_\_\_ FAILED \_\_\_\_\_ TABLED \_\_\_\_\_